Evidence map›Paper›PMID 41984951›Full record

Trial reportScience advances2026

Multiomics profiling and experiments in preclinical models revealed RAD51-IN-1 as a synergistic potentiator of anlotinib sensitivity.

Huangyang Meng, Qianjing Chang, Yashuang Zhang, Jingjing Ren, Hongyu Guo, Liang Yu, Cheng Qian, Yi Jiang, Lin Zhang, Wenjun Cheng

Registry-linked trialAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04807166 (A Prospective, Single-arm, Multicenter, Exploratory Phase II Study to Evaluate the Efficacy and Safety of Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04807166 phase2active not recruitingnot on this map

A Prospective, Single-arm, Multicenter, Exploratory Phase II Study to Evaluate the Efficacy and Safety of Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer

TypeinterventionalSponsorWenjun ChengRan2021 to 2027Enrolled56ConditionsOvarian Neoplasms, Fallopian Tube Neoplasms, Neoplasms by Site, Genital Neoplasms, FemaleArmsDrug: Anlotinib, Drug: Carboplatin/Paclitaxel
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Huangyang MengDepartment of Gynecology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu, Nanjing, 210029, China.ORCID 0000-0003-2662-915X
Qianjing ChangDepartment of Gynecology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu, Nanjing, 210029, China.
Yashuang ZhangDepartment of Gynecology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu, Nanjing, 210029, China.
Jingjing RenDepartment of Gynecology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu, Nanjing, 210029, China.
Hongyu GuoAffiliated Hospital of Nanjing University of Chinese Medicine and China Traditional Chinese Medicine Obstetrics and Gynecology Reproductive Clinical Medicine Innovation Center, Nanjing 210029, China.
Liang YuDepartment of Gynecology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu, Nanjing, 210029, China.
Cheng QianDepartment of Gynecology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu, Nanjing, 210029, China.
Yi JiangDepartment of Gynecology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu, Nanjing, 210029, China.
Lin ZhangDepartment of Gynecology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu, Nanjing, 210029, China.ORCID 0000-0002-5977-6589
Wenjun ChengDepartment of Gynecology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu, Nanjing, 210029, China.ORCID 0000-0002-5600-9982

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anlotinib has demonstrated preliminary efficacy as a first-line maintenance therapy for ovarian cancer. However, clinical responses vary widely. To investigate resistance mechanisms and explore rational combinations, pretreatment tumors from 18 patients in clinical trial NCT04807166 underwent whole-exome and RNA sequencing and stratified into sensitive and resistant groups based on progression-free survival. VEGFR-related mutations were enriched in sensitive tumors, whereas resistant tumors showed increased activity of DNA repair pathways and Notch signaling. In vitro screening identified strong synergy between anlotinib and the RAD51 inhibitor RAD51-IN-1, which outperformed the Notch inhibitor FLI-06 in resistant patient-derived organoids. Mechanistic studies revealed that RAD51 inhibition was associated with impaired HRR and increased sensitivity to anlotinib. In vivo, combined treatment with anlotinib and RAD51-IN-1 significantly reduced tumor burden without notable toxicity. These findings suggest that RAD51-mediated HRR may contribute to anlotinib resistance and support RAD51 inhibition as a promising approach to overcome therapeutic resistance in ovarian cancer.

Indexed as

IndolesOvarian NeoplasmsQuinolinesRad51 RecombinaseAnimalsCell Line, TumorDrug Resistance, NeoplasmDrug SynergismFemaleGene Expression ProfilingHumansMiceXenograft Model Antitumor AssaysanlotinibIndolesQuinolinesRad51 Recombinase

Identifiers

PMID41984951
PMCPMC13082322

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.